Thanks for the heads-up Rich. Since this is not an area of expertise for me, my health care sector investments are almost exclusively in large cap pharma with a dividend based income stream. If Daxi is approved and gains market share you may have a 10-bagger. My take on this is that Daxi will have to be accepted as a premium, or in their terminology, a prestige solution over Botox and avoid any serious competition in that area during the first year or two. ABBV paid $63B to acquire Botox three years ago. Maybe they'll be interested in RVNC if it makes sense.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.